Enzalutamide gets PBS listing
Enzalutamide, which is marketed as XTANDI, has gained PBS approval for men with castration-resistant metastatic prostate cancer (mCRPC).
The oral, once-daily androgen receptor signalling inhibitor that has been shown to decrease cancer cell growth and cause cancer cell death.
The reimbursement, available from December 1, is based on results from the phase III AFFIRM randomised controlled trial which showed enzalutamide improved overall survival, with a 37% reduction in risk of death compared with placebo.
The generally well tolerated